Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
Three propensity-matched cohorts of patients with nonvalvular atrial fibrillation who had incident exposure to dabigatran, rivaroxaban, or apixaban were compared.
An accompanying editorial said that based on the risk of gastrointestinal (GI) events found in this retrospective study, sodium polystyrene sulfonate should not be used to reduce serum potassium levels.
The drug was evaluated in three multicenter, phase 3, randomized, double-blind, placebo-controlled trials involving patients with moderately to severely active disease.
Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).
Although this study highlights a potential role of HPV status in the prognosis of esophageal adenocarcinoma, “the use of HPV as a predictive marker for treatment remains unproven,” an accompanying commentary
Endoscopic eradication therapy plus reflux control associated with decreased Barrett's recurrence rates
Standard reflux management protocol involved initial consultation that emphasized reflux control and proton-pump inhibitor (PPI) adherence, initiation or continuation of PPI therapy as described, medication reconciliation and assessment or
Initiating screening at age 45 years would require an additional 10 million colonoscopies, which could potentially provide greater benefit if used instead to increase screening rates in older patients, authors of the modeling study said.
Significant bleeding occurred in 2.5% of the patients on warfarin and 0.6% of the patients on non-vitamin K antagonist oral anticoagulants (NOACs).
A Taiwanese nationwide cohort study of more than 10,000 patients with chronic hepatitis B showed a statistically significant 29% risk reduction for hepatocellular carcinoma in patients who received daily aspirin compared with matched controls.